Literature DB >> 33490290

DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration.

Yanni Xu1,2, Qiongchao Jiang1,2, Hejun Liu3, Xiaoyun Xiao1, Dinghong Yang1, Phei Er Saw4, Baoming Luo1.   

Abstract

BACKGROUND: RNA helicases have various essential functions in basically all aspects of RNA metabolism, not only unwinding RNA but also disturbing the interaction of RNA with proteins. Recently, RNA helicases have been considered potential targets in cancers. So far, there has been no detailed investigation of the biological functions of RNA helicase DHX37 in cancers.
OBJECTIVE: We aim to identify the prognostic value of DHX37 associated with tumor microenvironments in cancers.
METHODS: DHX37 expression was examined via the Oncomine database and Tumor Immune Estimation Resource (TIMER). We explored the prognostic role of DHX37 in cancers across various databases. Coexpression genes, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG), and fundamental regulators were performed via LinkedOmics. Confirming the prognostic value of DHX37 in liver hepatocellular carcinoma (LIHC) and lung adenocarcinoma (LUAD), we explored the role of DHX37 in infiltrated lymphocytes in cancers using the Gene Expression Profiling Interactive Analysis (GEPIA) and TIMER databases.
RESULTS: Through GO and KEGG analyses, expression of DHX37 was also correlated with complex function-specific networks involving the ribosome and RNA metabolic signaling pathways. In LIHC and LUAD, DHX37 expression showed significant positive correlations with markers of Tregs, myeloid-derived suppressor cells (MDSCs), and T cell exhaustion, contributing to immune tolerance.
CONCLUSION: These results indicate that DHX37 can serve as a prognostic biomarker in LIHC and LUAD while having an important role in immune tolerance by activating the function of Tregs, MDSC, and T cell exhaustion.
Copyright © 2020 Yanni Xu et al.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33490290      PMCID: PMC7790560          DOI: 10.1155/2020/8835393

Source DB:  PubMed          Journal:  J Immunol Res        ISSN: 2314-7156            Impact factor:   4.818


  56 in total

Review 1.  Notch: the past, the present, and the future.

Authors:  Spyros Artavanis-Tsakonas; Marc A T Muskavitch
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

2.  ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer.

Authors:  Yuming Jiang; Qi Zhang; Yanfeng Hu; Tuanjie Li; Jiang Yu; Liying Zhao; Gengtai Ye; Haijun Deng; Tingyu Mou; Shirong Cai; Zhiwei Zhou; Hao Liu; Guihua Chen; Guoxin Li; Xiaolong Qi
Journal:  Ann Surg       Date:  2018-03       Impact factor: 12.969

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.

Authors:  Leticia Corrales; Daniel Ajona; Stavros Rafail; Juan J Lasarte; Jose I Riezu-Boj; John D Lambris; Ana Rouzaut; Maria J Pajares; Luis M Montuenga; Ruben Pio
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

Review 5.  Innate immune mediators in cancer: between defense and resistance.

Authors:  Pedro Berraondo; Luna Minute; Daniel Ajona; Leticia Corrales; Ignacio Melero; Ruben Pio
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 6.  RIG-I-like receptors and autoimmune diseases.

Authors:  Hiroki Kato; Takashi Fujita
Journal:  Curr Opin Immunol       Date:  2015-12       Impact factor: 7.486

7.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

Authors:  Gabriela Bindea; Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Maximilian Waldner; Anna C Obenauf; Helen Angell; Tessa Fredriksen; Lucie Lafontaine; Anne Berger; Patrick Bruneval; Wolf Herman Fridman; Christoph Becker; Franck Pagès; Michael R Speicher; Zlatko Trajanoski; Jérôme Galon
Journal:  Immunity       Date:  2013-10-17       Impact factor: 31.745

8.  DDX54 regulates transcriptome dynamics during DNA damage response.

Authors:  Miha Milek; Koshi Imami; Neelanjan Mukherjee; Francesca De Bortoli; Ulrike Zinnall; Orsalia Hazapis; Christian Trahan; Marlene Oeffinger; Florian Heyd; Uwe Ohler; Matthias Selbach; Markus Landthaler
Journal:  Genome Res       Date:  2017-06-08       Impact factor: 9.043

9.  DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients.

Authors:  Jieting Tang; Huarong Chen; Chi-Chun Wong; Dabin Liu; Tong Li; Xiaohong Wang; Jiafu Ji; Joseph Jy Sung; Jing-Yuan Fang; Jun Yu
Journal:  Oncogene       Date:  2018-03-14       Impact factor: 9.867

Review 10.  Immunotherapy in breast cancer.

Authors:  Soley Bayraktar; Sameer Batoo; Scott Okuno; Stefan Glück
Journal:  J Carcinog       Date:  2019-05-23
View more
  4 in total

1.  Machine Learning Screens Potential Drugs Targeting a Prognostic Gene Signature Associated With Proliferation in Hepatocellular Carcinoma.

Authors:  Jun Liu; Jianjun Lu; Wenli Li; Wenjie Mao; Yamin Lu
Journal:  Front Genet       Date:  2022-06-28       Impact factor: 4.772

2.  Identification of P2RY13 as an immune-related prognostic biomarker in lung adenocarcinoma: A public database-based retrospective study.

Authors:  Jiang Lin; Chunlei Wu; Dehua Ma; Quanteng Hu
Journal:  PeerJ       Date:  2021-05-05       Impact factor: 2.984

3.  Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.

Authors:  Hang Chen; Wei Shen; Saiqi Ni; Menglu Sang; Shibo Wu; Yinyu Mu; Kaitai Liu; Ni Li; Linwen Zhu; Guodong Xu
Journal:  Aging (Albany NY)       Date:  2021-08-26       Impact factor: 5.682

4.  ATIC facilitates cell growth and migration by upregulating Myc expression in lung adenocarcinoma.

Authors:  Niu Niu; Jialong Zeng; Xianni Ke; Wenyu Zheng; Chunmei Fu; Shiqi Lv; Jianghong Fu; Yang Yu
Journal:  Oncol Lett       Date:  2022-02-23       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.